Literature DB >> 12036391

How important are gender differences in pharmacokinetics?

Bernd Meibohm1, Ingrid Beierle, Hartmut Derendorf.   

Abstract

Gender-related differences in pharmacokinetics have frequently been considered as potentially important determinants for the clinical effectiveness of drug therapy. The mechanistic processes underlying gender-specific pharmacokinetics can be divided into molecular and physiological factors. Major molecular factors involved in drug disposition include drug transporters and drug-metabolising enzymes. Men seem to have a higher activity relative to women for the cytochrome P450 (CYP) isoenzymes CYP1A2 and potentially CYP2E1, for the drug efflux transporter P-glycoprotein, and for some isoforms of glucuronosyltransferases and sulfotransferases. Women were suggested to have a higher CYP2D6 activity. No major gender-specific differences seem to exist for CYP2C19 and CYP3A. The often-described higher hepatic clearance in women compared with men for substrates of CYP3A and P-glycoprotein, such as erythromycin and verapamil, may be explained by increased intrahepatocellular substrate availability due to lower hepatic P-glycoprotein activity in women relative to men. Physiological factors resulting in gender-related pharmacokinetic differences include the generally lower bodyweight and organ size, higher percentage of body fat, lower glomerular filtration rate and different gastric motility in women compared with men. Although gender disparity in pharmacokinetics has been identified for numerous drugs, differences are generally only subtle. For a few drugs, e.g. verapamil, beta-blockers and selective serotonin reuptake inhibitors, gender-related differences in pharmacokinetics have been shown to result in different pharmacological responses, but their clinical relevance remains unproven. In contrast, gender differences of clinical importance have clearly been identified for pharmacodynamic processes such as QTc prolongation, and intensive future research efforts are needed to assess the full scope and impact of pharmacodynamic gender disparity on applied pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036391     DOI: 10.2165/00003088-200241050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  153 in total

1.  Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice.

Authors: 
Journal:  Fed Regist       Date:  1993-07-22

Review 2.  Ethnicity and antipsychotic response.

Authors:  E J Frackiewicz; J J Sramek; J M Herrera; N M Kurtz; N R Cutler
Journal:  Ann Pharmacother       Date:  1997-11       Impact factor: 3.154

3.  Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.

Authors:  H G Xie; S L Huang; Z H Xu; Z S Xiao; N He; H H Zhou
Journal:  Pharmacogenetics       Date:  1997-04

4.  Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes.

Authors:  L C Wienkers; R C Steenwyk; P E Sanders; P G Pearson
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

5.  Gender differences in response to drugs: pain medications.

Authors:  J B Schwartz
Journal:  J Gend Specif Med       Date:  1999 Sep-Oct

6.  CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Weiling; B Wilffert; L F de Leij; R A de Zeeuw; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1999-05       Impact factor: 2.953

7.  Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.

Authors:  M E Krecic-Shepard; C R Barnas; J Slimko; J B Schwartz
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

8.  Influence of sex and oral contraceptive steroids on paracetamol metabolism.

Authors:  J O Miners; J Attwood; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

9.  Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.

Authors:  L C Wienkers; R C Steenwyk; M J Hauer; J C Fleishaker; P G Pearson
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

10.  Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.

Authors:  N F Kassell; E C Haley; C Apperson-Hansen; W M Alves
Journal:  J Neurosurg       Date:  1996-02       Impact factor: 5.115

View more
  95 in total

Review 1.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

2.  Factors affecting the anthelmintic efficacy of papaya latex in vivo: host sex and intensity of infection.

Authors:  Wenceslaus Luoga; Fadlul Mansur; Ann Lowe; Ian R Duce; David J Buttle; Jerzy M Behnke
Journal:  Parasitol Res       Date:  2015-04-10       Impact factor: 2.289

3.  Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats.

Authors:  Yan-Rong Ma; Hong-Yan Qin; Yong-Wen Jin; Jing Huang; Miao Han; Xing-Dong Wang; Guo-Qiang Zhang; Yan Zhou; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

6.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?

Authors:  Bui Tri Cuong; Vu Quoc Binh; Bui Dai; Dinh Ngoc Duy; Claire M Lovell; Karl H Rieckmann; Michael D Edstein
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

7.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Authors:  Vibha Bhatnagar; Erin P Garcia; Daniel T O'Connor; Victoria H Brophy; John Alcaraz; Erin Richard; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  Am J Nephrol       Date:  2009-11-12       Impact factor: 3.754

9.  Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.

Authors:  Jennypher Mudunuru; Chen Ren; David R Taft; Manoj Maniar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

Review 10.  A systematic review and combined meta-analysis of concentration of oral amisulpride.

Authors:  Lin Li; Lu Li; De-Wei Shang; Yu-Guan Wen; Yu-Ping Ning
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.